Navigation Links
Cellectar, Inc. Raises $13 Million in Private Offering
Date:1/8/2008

- Funds to Be Used for Phase 1 Clinical Trial -

MADISON, Wis., Jan. 8 /PRNewswire/ -- Cellectar, Inc., a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced that it has raised $13 million in a private offering. Cellectar will use the money to continue operations and execute a Phase 1 clinical trial for its lead oncology product candidate, CLR1404, which is planned to start this summer. Cellectar recently opened a new manufacturing facility in Madison, WI which will make it possible to complete its clinical trials while remaining independent.

The round was led by Venture Investors, LLC, with participants including Advantage Capital, several Wisconsin based angel investor groups, and a large private equity firm. John Neis, Managing Director of Venture Investors has joined the Cellectar Board of Directors.

Bill Clarke, M.D., Cellectar's President and CEO, commented, "Based on the encouraging data for our lead product candidate, CLR1404, these funds will allow us to move into the clinical trial phase of development. We are pleased with the confidence that our investors have in the Cellectar team. Additionally, John Neis brings a tremendous amount of experience to our Board and will be a key contributor not only to the management of our company, but also to our future fund raising efforts."

"Cellectar is another great example of a company formed around leading edge discoveries from major Midwestern research universities attracting a world class management team," said John Neis. "Cellectar has a lead pharmaceutical candidate that is well validated and has the potential to be an effective treatment for a wide variety of cancer types. Bill Clarke brings exceptional experience in the development of radiopharmaceuticals and has attracted a stellar team."

During 2007, Cellectar raised $7 million in the largest angel round in Wisconsin histo
'/>"/>

SOURCE Cellectar, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
2. Anesiva Raises $45 Million in Common Stock Offering
3. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
4. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
5. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. VisEn Medical Raises $7 Million in Series B Financing
8. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
9. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
10. Enobia Pharma Raises $40.1 Million Series B Financing
11. Pearl Therapeutics Raises $15.5 Million in Private Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 PMG Research, Inc. announced ... is a network of sites that provide clinical research services ... million patient lives through its partnerships with large physician practices ... hub site locations in the Southeastern United States and spans ... the board will be held by: Dr. Robert ...
(Date:11/26/2014)... CA (PRWEB) November 25, 2014 Silicon ... joins forces with RPM Alliance , provider of ... pharmaceutical companies. With the latest addition to its CRO ... free validated EDC system to India. , “We ... a robust and customizable EDC platform which is both ...
(Date:11/26/2014)... November 25, 2014 Global biostimulants ... 2019 growing at an estimated CAGR of 12.5%. ... healthy food products with least ecological impacts, farmers ... fertilizers to boost crop yield more effectively & ... that can improve the return on investments. , ...
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... ... for 87-Acre R&D/Manufacturing Facility , ... Philadelphia, Pa. (Vocus) September 8, 2009 -- BPG Properties, Ltd. ... 2750 Morris Road , a 705,000 square foot highly specialized research and development/manufacturing facility ...
... PriceSpective, a value strategy consultancy that provides ... pleased to announce that it has hired two senior experts ... President, and Sophie Murdoch, as a Director, will help further ... offerings. , , Colasante, who brings 20 ...
... , INCLINE VILLAGE, Nev., Sept. 8 ... announced revenue guidance for the third quarter ended September 30, ... for the third quarter of 2008. Royalty revenues are based ... $1.6 million for Synagis(R), which is marketed by MedImmune. When ...
Cached Biology Technology:BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale 2BPG Properties, Ltd. Announces 2750 Morris Road in Lansdale, Pennsylvania is for Sale 3PriceSpective Appoints Colasante as a Vice President and Murdoch as a Director 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the ... phase. In its first six months of existence, the Lab ... evidence support for local law enforcement. "Because our ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2
... from the United Kingdom, the Energy Department,s National Renewable ... recently published a paper describing a novel cellulose-degrading enzyme ... commonly known as the gribble. Gribbles are ... to produce their own enzymes instead of using symbiotic ...
... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ...
... Joshua Obar, Ph.D., Department of Immunology and Infectious ... 2013 ICAAC Young Investigator Award for his research on ... to infection. Obar earned his B.A. in ... on to complete his Ph.D. in Microbiology and Immunology ...
Cached Biology News:Novel enzyme from tiny gribble could prove a boon for biofuels research 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Evolutionarily conserved signaling intermediate in Toll pathway...
Phosphatidylinositol transfer protein beta isoform (PtdIns transfer protein beta) (PtdInsTP) (PI-TP-beta). [Source:Uniprot/SWISSPROT;Acc:P48739] Antigen: Recombinant Protein Epitope Signature Tag...
Biology Products: